AbbVie Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 56.20B | 58.05B | 54.32B | 56.33B | 61.16B | 8.6% | |
| Cost of Revenue | (17.45B) | (17.41B) | (20.41B) | (16.90B) | (18.20B) | 7.7% | |
Gross Profit | 38.75B | 40.64B | 33.90B | 39.43B | 42.96B | 8.9% | |
| Operating Expenses | |||||||
| Research & Development | (8.05B) | (6.51B) | (7.67B) | (12.79B) | (9.10B) | -28.9% | |
| Selling, General & Administrative | (12.35B) | (15.26B) | (12.87B) | (14.75B) | (14.01B) | -5.0% | |
| Depreciation & Amortization | (8.52B) | (8.47B) | (8.70B) | (8.39B) | (8.14B) | -2.9% | |
Operating Income (EBIT) | 17.92B | 18.12B | 12.76B | 9.14B | 20.09B | 119.9% | |
| Non-Operating Items | |||||||
| Interest Income | 39.00M | 186.00M | 540.00M | 648.00M | 266.00M | -59.0% | |
| Interest Expense | (2.42B) | (2.23B) | (2.22B) | (2.81B) | (2.89B) | 3.0% | |
| Other Income/Expenses (Net) | -4.93B | -4.64B | -6.51B | -5.42B | -13.49B | 148.9% | |
Income Before Tax | 12.99B | 13.48B | 6.25B | 3.72B | 6.60B | 77.5% | |
| Income Tax Expense | (1.44B) | (1.63B) | (1.38B) | (570.00M) | (2.36B) | -514.7% | |
Net Income | 11.54B | 11.84B | 4.86B | 4.28B | 4.23B | -1.2% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $6 | $7 | $3 | $2 | $2 | -1.2% | |
| Weighted Avg Shares Outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.78B | 0.6% | |
| Weighted Avg Shares Outstanding (Diluted) | 1.78B | 1.78B | 1.77B | 1.77B | 1.77B | 0.1% | |
EBITDA | 23.93B | 24.17B | 17.17B | 14.91B | 17.63B | 18.2% |
Explore ABBV
ABBV in the Healthcare
Mega Cap